Severe Adult Growth Hormone Deficiency

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Severe Adult Growth Hormone Deficiency trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (3 shown)

Active — Not RecruitingNot Applicable

NCT05230550

Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®

Participants are invited to take part in this study because they have AGHD (only severe case). The purpose of this study is to assess long term safety and effec…

Japan200 participantsStarted 2022-02-03

Treatment: Somapacitan

CompletedPhase 4

NCT01877512

GH and Cardiovascular Risk Factors

Rationale: Abnormally low and high levels of insulin-like growth factor-I (IGF-I) are both associated with increased metabolic risk. Since (U-shaped) associatio…

Netherlands32 participantsStarted 2013-05

Treatment: Change in daily dosage of Growth Hormone

TerminatedNot Applicable

NCT00468624

Effect of Pegvisomant on GH/IGF-I Relationship in GHD

Approximately 50% of middle-aged patients with severe AGHD have a normal age-related serum IGF-I. It remains unclear if in these individuals serum IGF-I is GH d…

United KingdomStarted 2004-12

Treatment: pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks, GH sampling - every 20 min over 24 hours after each limb (pegvisomant/placebo)